Otsuka in-licenses Harbour BioMed’s HBM7020
Japan’s Otsuka (TYO: 4578) has entered into an exclusive, worldwide licensing agreement with China and USA-based Harbour BioMed (HKEX: 02142) for the development and commercialization of HBM7020, a BCMAxCD3 bispecific T-cell engager under development by Harbour BioMed.
The license covers all territories worldwide except for Greater China (Mainland China, Hong Kong, Taiwan and Macau).
Otsuka said that HBM7020 has been confirmed in pre-clinical studies to activate T cells, which are part of the immune system, and bring them into close proximity with antibody producing B cells and plasma cells to induce cell destruction. Since many autoimmune diseases involve B cells and plasma cells that produce autoantibodies, HBM7020 is expected to have broad efficacy against these diseases. Otsuka plans to advance the development of HBM7020 as a therapeutic agent for autoimmune diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze